The application of anti-EGFR therapies, including monoclonal antibodies target at the receptor’s surface or tyrosine kinase inhibitors targeting its intracellular domain, has shown encouraging results in canine tumors [77,78,79,80] and oral squamous cell carcinoma in cats, particularly with Cetuximab [77]. Here, EGFR is linked to oral cavity squamous cell carcinoma.